2026-05-29 · non-surgical, procedures, comparison, weight-loss, ESG, gastric balloon

Non-Surgical Weight Loss Procedures Compared: ESG vs Gastric Balloon vs Gastric Band

Quick answer

Non-surgical weight loss procedures — primarily endoscopic sleeve gastroplasty (ESG) and the intragastric balloon — are less invasive and (in the balloon’s case) reversible, but they produce less total weight loss than bariatric surgery. Adjustable gastric banding (AGB) is technically a laparoscopic surgery but is often grouped with the less invasive options because it does not remove or reroute any part of the digestive tract; it is the most invasive of the three procedures compared here. If your goal is more than roughly 20% total body weight loss, a sleeve gastrectomy or gastric bypass will usually deliver more durable results — see the bariatric surgery types compared hub for that side-by-side.

Side-by-side comparison

TBWL = total body weight loss. Ranges are drawn from the cited literature; individual results vary. AGB is included here as the “least invasive surgical” option for comparison — it is more invasive than ESG or the balloon and is also covered in the surgical hub.

Procedure summaries

Endoscopic sleeve gastroplasty (ESG)

Endoscopic sleeve gastroplasty is a non-incisional procedure performed through the mouth using a flexible endoscope and an endoscopic suturing system. The stomach is folded and stitched into a narrow tube similar in shape to a surgical sleeve, but no tissue is removed. Most patients go home the same day, and downtime is typically a few days.

The MERIT randomized trial, published in The Lancet in 2022, reported a mean total body weight loss of about 13.6% at 52 weeks among patients with class 1 and class 2 obesity. Pooled meta-analyses including ESG-vs-sleeve comparisons consistently show ESG producing less total weight loss than surgical sleeve gastrectomy but more than the balloon, with results typically in the 15–20% TBWL range by 12–18 months when patients stay engaged with nutrition follow-up.

ESG is most commonly offered to patients in the BMI 30–40 range, where many bariatric surgery programs would not yet recommend a sleeve or bypass. It is not a fit for patients with prior stomach surgery or a large hiatal hernia, and it still requires a structured nutrition program to hold the loss.

Intragastric balloon

Gastric balloon procedures place a saline- or gas-filled balloon in the stomach to occupy space, slow gastric emptying, and help patients feel full on smaller portions. The classic device (Orbera) is placed and removed endoscopically and stays in for 6 months. Newer swallowable systems (Obalon) use capsules that the patient swallows and that are removed endoscopically at the end of the treatment window.

Average weight loss in pivotal trials and large multicenter studies is about 10–15% of total body weight at the time of removal. The U.S. multicenter Orbera study published in Surgery for Obesity and Related Diseases documented these results across more than 300 patients. The balloon is the least invasive option in this comparison: there are no incisions, no implanted long-term hardware, and no anatomy change. The trade-off is durability — meaningful regain after removal is common unless the patient has built sustainable eating and activity routines during the 6-month treatment window.

The balloon is best framed as a 6-month jump-start that buys time and momentum, not as a stand-alone solution.

Adjustable gastric banding (AGB)

Adjustable gastric banding places an inflatable silicone band around the upper stomach, creating a small pouch above the band. A port under the skin lets the surgeon tighten or loosen the band over time by adding or removing saline. AGB is a laparoscopic surgery — more invasive than ESG or the balloon — but it is included in this hub because it is fully reversible, does not remove or reroute tissue, and patients often compare it to the endoscopic options when they specifically want a reversible device.

Long-term outcome studies, including a 12-year prospective cohort in Annals of Surgery, have shown lower total weight loss than sleeve gastrectomy or gastric bypass and high rates of reoperation for slippage, erosion, port problems, or inadequate weight loss. As a result, AGB has fallen sharply in U.S. use over the past decade and now accounts for fewer than 1% of bariatric procedures in recent ASMBS estimates. It remains an option at select centers for patients who specifically want a reversible, non-resective device and are willing to attend frequent adjustment visits.

How to choose

There is no single “best” non-surgical option. The decision is built from a few inputs:

• BMI and weight-loss goal. ESG and the balloon fit best for patients at BMI 30–40 who want a moderate amount of weight loss. If you need more than roughly 20% total body weight loss, the cited evidence supports stepping up to a sleeve gastrectomy or gastric bypass rather than expecting a non-surgical procedure to deliver it.
• Reversibility and durability preference. The balloon is temporary by design. ESG aims to be a long-term intervention but does not remove any tissue. AGB is fully reversible, but reversal itself is surgical.
• Invasiveness tolerance. The balloon is the least invasive. ESG involves an endoscopic procedure under sedation with no incisions. AGB is a laparoscopic surgery with small incisions and a longer recovery.
• Comorbidity priorities. Type 2 diabetes and severe GERD generally push toward bariatric surgery — particularly gastric bypass — rather than a non-surgical option, because the hormonal and weight-loss benefits are larger.
• Cost and access. ESG and the balloon are usually self-pay (commonly $6,000–$13,000 in the U.S.) because most insurers still consider them investigational. AGB is sometimes covered when offered as a primary bariatric option, but coverage has narrowed.
• Willingness to commit to follow-up. All three require a structured nutrition program. AGB additionally requires periodic in-office band adjustments, often several times in the first year.

When to consider bariatric surgery instead

If your starting BMI is well above 40, if you have type 2 diabetes or severe GERD, or if your weight-loss goal is more than roughly 20% of total body weight, the evidence supports moving up to a bariatric surgery rather than choosing a non-surgical option. The bariatric surgery overview covers eligibility, the pre-op workup, and what long-term follow-up looks like, and the bariatric surgery types compared hub lays out gastric bypass, sleeve gastrectomy, AGB, and revision side by side. ESG and the balloon are reasonable first steps when goals are moderate, but they are not designed to deliver the weight loss seen with sleeve or bypass.

Risks and trade-offs

Every option here has trade-offs:

• Intragastric balloon. Early nausea and vomiting are very common in the first 1–2 weeks. Rare but more serious complications include balloon deflation, migration, gastric ulcer, and intolerance leading to early removal. Regain after removal is common without structured habit support.
• ESG. Nausea, cramping, and reflux can occur, and durability remains less certain than for surgical sleeve. Most patients are followed for ongoing nutrition coaching, and some need a touch-up procedure later.
• Adjustable gastric banding. Slippage, erosion, port problems, and esophageal dilation can occur, and pooled long-term data show roughly 40–50% of patients ultimately need reoperation or band removal. If a band is not delivering weight loss or is causing complications, conversion to sleeve or bypass is a well-established option — see bariatric surgery revision for what conversion typically involves.

Across all three options, weight regain is the most common long-term issue, and durable results depend on consistent nutrition, activity, and follow-up rather than the procedure alone.

Frequently asked questions

What is the least invasive weight loss procedure? The intragastric balloon is the least invasive option. It is placed endoscopically through the mouth, requires no incisions, and is removed at 6 months. ESG is also non-incisional but uses internal sutures that are intended to stay in place long-term. AGB is the most invasive of the three because it is a laparoscopic surgery that places an implanted silicone device around the stomach.

Gastric balloon vs ESG — which loses more weight? ESG produces more weight loss than the balloon in head-to-head data. The MERIT randomized trial reported about 13.6% total body weight loss with ESG at 12 months, and most ESG meta-analyses land in the 15–20% TBWL range over 12–18 months. Intragastric balloons typically produce 10–15% TBWL at 6 months in pooled trial data, with regain after the balloon is removed unless habit changes hold.

Are non-surgical weight loss procedures permanent? No. The intragastric balloon is temporary by design and is removed at 6 months. ESG is technically reversible because no tissue is removed, but the sutures are not routinely undone — it is intended as a long-term intervention. AGB is fully reversible: the band and port can be removed and the stomach returns to its original shape, though removal is itself a surgical procedure.

Who qualifies for a non-surgical procedure instead of bypass or sleeve? ESG and the gastric balloon are most often offered at BMI 30–40, where many bariatric surgery programs would not yet recommend a sleeve or bypass. The 2022 ASMBS/IFSO indications support bariatric surgery at BMI ≥35 (regardless of comorbidity) and ≥30 with metabolic disease, but real-world insurance criteria often lag. Patients who decline surgery because of recovery time, scarring, anesthesia risk, or concerns about permanent anatomy change may also be candidates for ESG or a balloon.

How much do non-surgical weight loss procedures cost? U.S. self-pay pricing for ESG is commonly $8,000–$13,000 and for the intragastric balloon $6,000–$9,000, with placement, anesthesia, and facility fees typically bundled. Most insurers still classify ESG and the balloon as investigational and do not cover them, though coverage for follow-up nutrition support is more common than coverage for the procedure itself. AGB is more often partly covered when offered as a primary bariatric option, but coverage has narrowed as banding has fallen out of first-line use.

How do non-surgical procedures compare to GLP-1 medications? ESG and the gastric balloon work mechanically by limiting stomach capacity, while GLP-1 medications work hormonally by reducing appetite and slowing gastric emptying. Average weight loss is broadly similar — typically 10–20% of total body weight — but GLP-1 results often regress once the medication is stopped, while ESG aims for a more durable effect. Many programs now combine the two.